Ontology type: schema:ScholarlyArticle Open Access: True
2018-06-29
AUTHORSHideki Kato, Yoshitaka Miyakawa, Yoshihiko Hidaka, Norimitsu Inoue, Shuichi Ito, Shoji Kagami, Shinya Kaname, Masanori Matsumoto, Masashi Mizuno, Takahisa Matsuda, Akihiko Shimono, Shoichi Maruyama, Yoshihiro Fujimura, Masaomi Nangaku, Hirokazu Okada
ABSTRACTBackgroundEculizumab has been available for the treatment of atypical hemolytic–uremic syndrome (aHUS) in Japan since 2013. To assess safety and effectiveness of eculizumab in adult aHUS patients in the real-life setting, we performed interim analysis of a post-marketing surveillance mandated by Japanese regulations.MethodsThis study enrolled any patient who was diagnosed with TMA excluding Shiga toxin-producing Escherichia coli-HUS or thrombotic thrombocytopenic purpura based on Japanese clinical guide published in 2013 as inclusion criteria and treated with eculizumab. Although the term aHUS was redefined to denote only complement-mediated HUS in the guide revised in 2016, the patients with TMA caused by other causes (secondary TMA) were included. Patient outcomes and safety were evaluated at 6 months, 12 months, and annually thereafter.ResultsThirty-three patients with aHUS and 27 patients with secondary TMA were enrolled. Median treatment duration of aHUS was 24weeks. Complement genes variants were detected in 11 of 18 patients with aHUS (61.1%). Among the 29 aHUS patients with available baseline data, platelet count (PLT), lactic dehydrogenase and serum creatinine (SCr) improved within 1-month after eculizumab initiation. TMA event-free status, complete TMA response, PLT normalization, and SCr decrease were achieved in 67.9% (19/28), 27.8% (5/18), 56.5% (13/23), and 57.1% (16/28) of patients, respectively. Thirty-three and 11 adverse reactions were observed in patients with aHUS (13/33 patients) and secondary TMA (6/27 patients), respectively.ConclusionsThis interim analysis confirmed the acceptable safety profile and effectiveness of eculizumab for Japanese adult aHUS patients in real-world settings. More... »
PAGES65-75
http://scigraph.springernature.com/pub.10.1007/s10157-018-1609-8
DOIhttp://dx.doi.org/10.1007/s10157-018-1609-8
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1105208689
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/29959568
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Public Health and Health Services",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antibodies, Monoclonal, Humanized",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Atypical Hemolytic Uremic Syndrome",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Complement C5",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Complement Inactivating Agents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Complement System Proteins",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Genetic Variation",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Japan",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Kidney Function Tests",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Patient Safety",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Product Surveillance, Postmarketing",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Young Adult",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Division of Nephrology and Endocrinology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.26999.3d",
"name": [
"Division of Nephrology and Endocrinology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Kato",
"givenName": "Hideki",
"id": "sg:person.01275753007.55",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275753007.55"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of General Internal Medicine, Thrombosis and Hemostasis Center, Saitama Medical University, 38 Moroyama, Iruma-gun, 350-0495, Saitama, Japan",
"id": "http://www.grid.ac/institutes/grid.410802.f",
"name": [
"Department of General Internal Medicine, Thrombosis and Hemostasis Center, Saitama Medical University, 38 Moroyama, Iruma-gun, 350-0495, Saitama, Japan"
],
"type": "Organization"
},
"familyName": "Miyakawa",
"givenName": "Yoshitaka",
"id": "sg:person.01317475506.36",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317475506.36"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Clinical Division of Pediatrics, Shinshu University Hospital, 3-1-1 Asahi, 390-8621, Matsumoto, Nagano, Japan",
"id": "http://www.grid.ac/institutes/grid.412568.c",
"name": [
"Clinical Division of Pediatrics, Shinshu University Hospital, 3-1-1 Asahi, 390-8621, Matsumoto, Nagano, Japan"
],
"type": "Organization"
},
"familyName": "Hidaka",
"givenName": "Yoshihiko",
"id": "sg:person.01366756522.36",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01366756522.36"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Tumor Immunology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, 541-8567, Osaka, Japan",
"id": "http://www.grid.ac/institutes/grid.489169.b",
"name": [
"Department of Tumor Immunology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, 541-8567, Osaka, Japan"
],
"type": "Organization"
},
"familyName": "Inoue",
"givenName": "Norimitsu",
"id": "sg:person.010564733752.03",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010564733752.03"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Pediatrics, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanasawa-ku, 236-0004, Yokohama, Kanagawa, Japan",
"id": "http://www.grid.ac/institutes/grid.268441.d",
"name": [
"Department of Pediatrics, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanasawa-ku, 236-0004, Yokohama, Kanagawa, Japan"
],
"type": "Organization"
},
"familyName": "Ito",
"givenName": "Shuichi",
"id": "sg:person.012302533312.63",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012302533312.63"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Pediatrics, Institute of Health Biosciences, The University of Tokushima Graduate School, Kuramoto cho 3-chome, 770-8503, Tokushima, Japan",
"id": "http://www.grid.ac/institutes/grid.267335.6",
"name": [
"Department of Pediatrics, Institute of Health Biosciences, The University of Tokushima Graduate School, Kuramoto cho 3-chome, 770-8503, Tokushima, Japan"
],
"type": "Organization"
},
"familyName": "Kagami",
"givenName": "Shoji",
"id": "sg:person.01227336036.26",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01227336036.26"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Nephrology and Rheumatology, Kyorin University School of Medicine, 6-20-2 Shinkawa, 181-8611, Mitaka, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.411205.3",
"name": [
"Department of Nephrology and Rheumatology, Kyorin University School of Medicine, 6-20-2 Shinkawa, 181-8611, Mitaka, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Kaname",
"givenName": "Shinya",
"id": "sg:person.0632351573.32",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632351573.32"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Blood Transfusion Medicine, Nara Medical University, 840 Shijyo-cho, 634-8522, Kashihara, Nara, Japan",
"id": "http://www.grid.ac/institutes/grid.410814.8",
"name": [
"Department of Blood Transfusion Medicine, Nara Medical University, 840 Shijyo-cho, 634-8522, Kashihara, Nara, Japan"
],
"type": "Organization"
},
"familyName": "Matsumoto",
"givenName": "Masanori",
"id": "sg:person.013301731152.54",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013301731152.54"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Renal Replacement Therapy, Division of Nephrology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Aichi, Japan",
"id": "http://www.grid.ac/institutes/grid.27476.30",
"name": [
"Renal Replacement Therapy, Division of Nephrology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Aichi, Japan"
],
"type": "Organization"
},
"familyName": "Mizuno",
"givenName": "Masashi",
"id": "sg:person.01211430102.94",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01211430102.94"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Alexion Pharma GK, 1-18-14 Ebisu, Shibuya-ku, 150-0013, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Alexion Pharma GK, 1-18-14 Ebisu, Shibuya-ku, 150-0013, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Matsuda",
"givenName": "Takahisa",
"id": "sg:person.014167142054.61",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014167142054.61"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Alexion Pharma GK, 1-18-14 Ebisu, Shibuya-ku, 150-0013, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Alexion Pharma GK, 1-18-14 Ebisu, Shibuya-ku, 150-0013, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Shimono",
"givenName": "Akihiko",
"id": "sg:person.014764522454.27",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014764522454.27"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Nephrology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Aichi, Japan",
"id": "http://www.grid.ac/institutes/grid.27476.30",
"name": [
"Department of Nephrology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, 466-8550, Nagoya, Aichi, Japan"
],
"type": "Organization"
},
"familyName": "Maruyama",
"givenName": "Shoichi",
"id": "sg:person.01106355134.42",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01106355134.42"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Japanese Red Cross Kinki Block Blood Center, 7-5-17, Saitoasagi, 567-0085, Ibaraki, Osaka, Japan",
"id": "http://www.grid.ac/institutes/grid.410775.0",
"name": [
"Japanese Red Cross Kinki Block Blood Center, 7-5-17, Saitoasagi, 567-0085, Ibaraki, Osaka, Japan"
],
"type": "Organization"
},
"familyName": "Fujimura",
"givenName": "Yoshihiro",
"id": "sg:person.0724065021.42",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0724065021.42"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Division of Nephrology and Endocrinology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.26999.3d",
"name": [
"Division of Nephrology and Endocrinology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Nangaku",
"givenName": "Masaomi",
"id": "sg:person.01300062465.65",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300062465.65"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Department of Nephrology, Saitama Medical University, 38 Moroyama, Iruma-gun, 350-0495, Saitama, Japan",
"id": "http://www.grid.ac/institutes/grid.410802.f",
"name": [
"Department of Nephrology, Saitama Medical University, 38 Moroyama, Iruma-gun, 350-0495, Saitama, Japan"
],
"type": "Organization"
},
"familyName": "Okada",
"givenName": "Hirokazu",
"id": "sg:person.0700630035.01",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0700630035.01"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1007/s10157-016-1276-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1023786470",
"https://doi.org/10.1007/s10157-016-1276-6"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10157-013-0911-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1015777021",
"https://doi.org/10.1007/s10157-013-0911-8"
],
"type": "CreativeWork"
}
],
"datePublished": "2018-06-29",
"datePublishedReg": "2018-06-29",
"description": "BackgroundEculizumab has been available for the treatment of atypical hemolytic\u2013uremic syndrome (aHUS) in Japan since 2013. To assess safety and effectiveness of eculizumab in adult aHUS patients in the real-life setting, we performed interim analysis of a post-marketing surveillance mandated by Japanese regulations.MethodsThis study enrolled any patient who was diagnosed with TMA excluding Shiga toxin-producing Escherichia coli-HUS or thrombotic thrombocytopenic purpura based on Japanese clinical guide published in 2013 as inclusion criteria and treated with eculizumab. Although the term aHUS was redefined to denote only complement-mediated HUS in the guide revised in 2016, the patients with TMA caused by other causes (secondary TMA) were included. Patient outcomes and safety were evaluated at 6 months, 12 months, and annually thereafter.ResultsThirty-three patients with aHUS and 27 patients with secondary TMA were enrolled. Median treatment duration of aHUS was 24weeks. Complement genes variants were detected in 11 of 18 patients with aHUS (61.1%). Among the 29 aHUS patients with available baseline data, platelet count (PLT), lactic dehydrogenase and serum creatinine (SCr) improved within 1-month after eculizumab initiation. TMA event-free status, complete TMA response, PLT normalization, and SCr decrease were achieved in 67.9% (19/28), 27.8% (5/18), 56.5% (13/23), and 57.1% (16/28) of patients, respectively. Thirty-three and 11 adverse reactions were observed in patients with aHUS (13/33 patients) and secondary TMA (6/27 patients), respectively.ConclusionsThis interim analysis confirmed the acceptable safety profile and effectiveness of eculizumab for Japanese adult aHUS patients in real-world settings.",
"genre": "article",
"id": "sg:pub.10.1007/s10157-018-1609-8",
"inLanguage": "en",
"isAccessibleForFree": true,
"isFundedItemOf": [
{
"id": "sg:grant.5898832",
"type": "MonetaryGrant"
},
{
"id": "sg:grant.6835634",
"type": "MonetaryGrant"
}
],
"isPartOf": [
{
"id": "sg:journal.1117096",
"issn": [
"1342-1751",
"1437-7799"
],
"name": "Clinical and Experimental Nephrology",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "23"
}
],
"keywords": [
"atypical hemolytic uremic syndrome",
"effectiveness of eculizumab",
"hemolytic uremic syndrome",
"post-marketing surveillance",
"interim analysis",
"secondary TMA",
"serum creatinine",
"aHUS patients",
"platelet count",
"Shiga toxin-producing Escherichia",
"complement-mediated HUS",
"ResultsThirty-three patients",
"event-free status",
"complete TMA response",
"median treatment duration",
"acceptable safety profile",
"thrombotic thrombocytopenic purpura",
"complement gene variants",
"available baseline data",
"adult patients",
"thrombocytopenic purpura",
"safety profile",
"eculizumab initiation",
"adverse reactions",
"patient outcomes",
"clinical guide",
"inclusion criteria",
"MethodsThis study",
"patients",
"treatment duration",
"eculizumab",
"real-world setting",
"real-life setting",
"aHUS patients",
"gene variants",
"lactic dehydrogenase",
"baseline data",
"syndrome",
"months",
"safety",
"surveillance",
"TMA response",
"purpura",
"creatinine",
"SCR decrease",
"setting",
"outcomes",
"treatment",
"HUS",
"cause",
"duration",
"count",
"TMA",
"status",
"initiation",
"response",
"effectiveness",
"normalization",
"dehydrogenase",
"decrease",
"criteria",
"analysis",
"study",
"variants",
"regulation",
"guide",
"Escherichia",
"Japan",
"profile",
"Japanese regulations",
"data",
"reaction"
],
"name": "Safety and effectiveness of eculizumab for adult patients with atypical hemolytic\u2013uremic syndrome in Japan: interim analysis of post-marketing surveillance",
"pagination": "65-75",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1105208689"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s10157-018-1609-8"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"29959568"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s10157-018-1609-8",
"https://app.dimensions.ai/details/publication/pub.1105208689"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-10T10:19",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_784.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s10157-018-1609-8"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10157-018-1609-8'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10157-018-1609-8'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10157-018-1609-8'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10157-018-1609-8'
This table displays all metadata directly associated to this object as RDF triples.
349 TRIPLES
22 PREDICATES
117 URIs
107 LITERALS
25 BLANK NODES